Guardant Health (NASDAQ:GH) Shares Gap Up to $20.25

Guardant Health, Inc. (NASDAQ:GHGet Free Report)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $20.25, but opened at $22.25. Guardant Health shares last traded at $20.61, with a volume of 1,120,927 shares traded.

Wall Street Analyst Weigh In

GH has been the topic of a number of recent research reports. Canaccord Genuity Group reduced their target price on shares of Guardant Health from $50.00 to $45.00 and set a “buy” rating on the stock in a report on Friday, February 23rd. Piper Sandler dropped their target price on shares of Guardant Health from $40.00 to $30.00 and set an “overweight” rating for the company in a research report on Monday, February 26th. Wolfe Research began coverage on shares of Guardant Health in a research report on Wednesday, December 13th. They set a “peer perform” rating for the company. JPMorgan Chase & Co. lowered their price objective on shares of Guardant Health from $60.00 to $45.00 and set an “overweight” rating for the company in a research report on Friday, February 23rd. Finally, The Goldman Sachs Group lowered their price objective on shares of Guardant Health from $43.00 to $37.00 and set a “buy” rating for the company in a research report on Monday, January 29th. Two investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat, Guardant Health currently has a consensus rating of “Moderate Buy” and an average price target of $41.30.

View Our Latest Stock Report on Guardant Health

Guardant Health Price Performance

The company has a debt-to-equity ratio of 7.18, a quick ratio of 6.24 and a current ratio of 6.54. The stock has a 50-day simple moving average of $20.45 and a 200 day simple moving average of $24.16.

Guardant Health (NASDAQ:GHGet Free Report) last announced its quarterly earnings results on Thursday, February 22nd. The company reported ($1.58) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.93) by ($0.65). The firm had revenue of $155.05 million for the quarter, compared to analyst estimates of $151.71 million. Guardant Health had a negative net margin of 85.02% and a negative return on equity of 301.94%. Equities analysts expect that Guardant Health, Inc. will post -3.49 EPS for the current year.

Insider Transactions at Guardant Health

In other Guardant Health news, insider Kumud Kalia purchased 2,187 shares of the business’s stock in a transaction dated Monday, March 18th. The stock was bought at an average cost of $17.82 per share, for a total transaction of $38,972.34. Following the completion of the acquisition, the insider now directly owns 12,722 shares in the company, valued at $226,706.04. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 6.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of GH. CWM LLC boosted its holdings in Guardant Health by 137.1% in the third quarter. CWM LLC now owns 984 shares of the company’s stock valued at $29,000 after acquiring an additional 569 shares during the last quarter. BluePath Capital Management LLC acquired a new position in Guardant Health in the third quarter valued at about $35,000. Acadian Asset Management LLC acquired a new position in Guardant Health in the first quarter valued at about $37,000. Captrust Financial Advisors raised its position in shares of Guardant Health by 33.2% during the second quarter. Captrust Financial Advisors now owns 1,087 shares of the company’s stock worth $44,000 after purchasing an additional 271 shares during the period. Finally, Headlands Technologies LLC raised its position in shares of Guardant Health by 362.3% during the fourth quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock worth $64,000 after purchasing an additional 1,844 shares during the period. 92.60% of the stock is currently owned by institutional investors and hedge funds.

About Guardant Health

(Get Free Report)

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Featured Stories

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.